![Kurt von Emster](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kurt von Emster
Directeur/Membre du Conseil chez
JASPER THERAPEUTICS, INC.
Fortune : 1 755 $ au 31/05/2026
Profil
Konrad Hans von Emster was the founder of Franklin Biotechnology Discovery Fund (2001, Portfolio Manager) and venBio Partners LLC (2009, Managing Partner).
Current jobs include Director at SFJ Pharmaceuticals, Inc. (2020), Director at Iambic Therapeutics, Inc. (2023), Director at Orbus Therapeutics, Inc. (2020), Director at Tizona Therapeutics, Inc. (2020), Director at Abingworth Bioventures GP Ltd. (2019), Director at Jasper Tx Corp.
(2019), Independent Director at Jasper Therapeutics, Inc. (2021), Managing Partner at Abingworth Management Ltd. (2015), Managing Partner & Head of Life Sciences at Abingworth LLP (2015), Member at CFA Institute, and Partner at Broadhaven Capital Partners (Private equity) (2017).
Former jobs include Chairman at Kesios Therapeutics Ltd., Chairman at Vera Therapeutics, Inc. (2020-2022), Managing Director at MPM BioEquities Adviser LLC (2000-2009), Independent Director at Somaxon Pharmaceuticals, Inc. (2005-2013), Director at Abbott Biotherapeutics Corp.
(2009-2010), Managing Director at MPM BioImpact LLC (2001-2009), Director at Launch Therapeutics, Inc., Director at Cytos Biotechnology AG (2012-2015), Director at Facet, Inc., Independent Director at Aurinia Pharmaceuticals, Inc. (2014-2015), Independent Non-Executive Director at CRISPR Therapeutics AG (2015-2019), Independent Director at Vaxcyte, Inc. (2021-2022), Director at Attenua, Inc., Independent Director at CymaBay Therapeutics, Inc. (2009-2024), Director at Trishula Therapeutics, Inc. (2020-2021), Vice President at Franklin Resources, Inc., Principal at Acceleron Pharma, Inc., Vice President at Franklin Advisers, Inc., Member at CFA Society of San Francisco, Vice President & Portfolio Manager at Franklin Templeton Cos.
LLC, and Portfolio Manager & Vice President at Franklin Templeton Switzerland Ltd. (1989-2000).
Education includes an undergraduate degree from the University of California, Santa Barbara (1989).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 2 117 ( 0,01% ) | 1 755 $ | 31/05/2026 |
Postes actifs de Kurt von Emster
| Sociétés | Poste | Début |
|---|---|---|
| JASPER THERAPEUTICS, INC. | Directeur/Membre du Conseil | 24/09/2021 |
Jasper Tx Corp.
 Jasper Tx Corp. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company which engages in enabling cures through hematopoietic stem cell therapy | Directeur/Membre du Conseil | 01/11/2019 |
SFJ Pharmaceuticals, Inc.
 SFJ Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops pharmaceuticals drugs | Directeur/Membre du Conseil | 01/04/2020 |
Orbus Therapeutics, Inc.
 Orbus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delevops products that treat rare diseases | Directeur/Membre du Conseil | 01/07/2020 |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Develops and manufactures immuno therapies | Directeur/Membre du Conseil | 01/12/2020 |
Broadhaven Capital Partners (Private equity)
 Broadhaven Capital Partners (Private equity) Investment ManagersFinance Broadhaven Capital Partners invests in companies located in the United States. The firm focuses on financial services and technology sectors. It participates in seed and early equity investments. | Private Equity Investor | 01/05/2017 |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth invests in both private and public companies located across Europe and the United States. The firm targets companies operating in the fields of life sciences and healthcare sectors. It provide financing for seed, early, later and clinical co-development stage capital requirements with an investment size of USD 15 - 30 million. | Private Equity Investor | 01/01/2015 |
Abingworth Bioventures GP Ltd.
 Abingworth Bioventures GP Ltd. Other TransportationTransportation Provides marine cargo handling facilities | Directeur/Membre du Conseil | 16/09/2019 |
CFA Institute
 CFA Institute Miscellaneous Commercial ServicesCommercial Services Operates as an association of investment professionals | Corporate Officer/Principal | - |
| ░░░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Kurt von Emster
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Kurt von Emster
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
65
Relations au 1er degré
35
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 35 |
|---|---|
Franklin Resources, Inc.
 Franklin Resources, Inc. Investment ManagersFinance Operates as a holding company which provides investment management services | Finance |
MPM BioEquities Adviser LLC
 MPM BioEquities Adviser LLC Investment ManagersFinance MPM BioEquities Adviser focuses exclusively on global life sciences investments. The firm invests in biotechnology, specialty pharmaceuticals, medical technology and related companies that provide innovative medical products and services to the healthcare industry. They invest across all geographies, stages of development and therapeutic areas. MPM focuses on inflection points in the development of companies, such as the achievement of clinical proof-of-concept data and the achievement of early commercial success, and on reinvigorating commercial platforms with potentially high growth assets. MPM BioVentures I (BB BioVentures, MPM BioVentures Parallel Fund) is a family of funds that was launched in 1997 and is no fully committed with 75% of its investments in biotechnology and 25% in medical devices and other healthcare related fields. The MPM BioVentures I portfolio consists of 26 companies with investments ranging from $5 million to $20 million per company. Within the biotechnology sector, the funds' investments are split between companies focused on therapeutics and enabling technologies. About 80% of the funds' assets are invested in US companies and 20% in European companies. The MPM BioVentures II family of funds closed in the first quarter of 2000. The funds consist of investments in biotechnology, medical devices and other healthcare related fields. The MPM BioVentures II has invested in 35 companies, with investments ranging from $10 million to $50 million. The fund has invested across the entire spectrum of company development, from start-up through mezzanine and PIPES. 85% of the funds' investments are in US companies and 15% are in European and Asian companies. The MPM BioVentures III Fund closed in December of 2002. The fund holds a portfolio of 39 companies, 85% of which are focused on biotechnology and pharmaceutical products and 15% are focused on medical devices and life science tools. The fund's balanced portfolio of early-, mid- and late-stage companies includes investments in public companies through PIPE transactions. The MPM BioVentures IV family of funds was launched in the second quarter of 2006. The funds hold a portfolio of 18 companies with investments ranging from $5 million to $36 million. About 75% of the funds' investments focus on biotechnology and pharmaceutical products and 25% focus on medical device companies. About 25% of the funds' investments have been made outside the US, including investments in Asia and Europe. The MPM BioVentures IV family of funds serves as the lead investor in a majority of its investments and takes an active role as a board member on its portfolio companies' boards of directors. | Finance |
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for people with life-threatening diseases | Health Technology |
Somaxon Pharmaceuticals, Inc.
 Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Health Technology |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company which develops protein therapeutics for cancer and orphan diseases | Health Technology |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for the treatment of oncology and immunologic diseases | Health Technology |
Abingworth Management Ltd.
 Abingworth Management Ltd. Investment ManagersFinance Operates as an investment firm | Finance |
Franklin Biotechnology Discovery Fund
 Franklin Biotechnology Discovery Fund Investment Trusts/Mutual FundsMiscellaneous Acts as Open-End Investment Fund/Unit Trust | Miscellaneous |
Franklin Advisers, Inc.
 Franklin Advisers, Inc. Investment ManagersFinance Franklin Advisers provides advisory services to a range of products and separate accounts which utilize various investment strategies including equity, fixed income, core, hybrid, and multi-asset strategies. The firm employs fundamental, bottom-up investment analysis to select securities within a specific sector or industry. | Finance |
MPM BioImpact LLC
 MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth invests in both private and public companies located across Europe and the United States. The firm targets companies operating in the fields of life sciences and healthcare sectors. It provide financing for seed, early, later and clinical co-development stage capital requirements with an investment size of USD 15 - 30 million. | Finance |
Cytos Biotechnology AG
 Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Discovers and develops new protein drugs and innovative therapeutic concepts | Commercial Services |
Facet, Inc.
 Facet, Inc. Information Technology ServicesTechnology Services Manufactures library creation and maintenance software | Technology Services |
University of California, Santa Barbara
 University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CFA Institute
CFA Institute Miscellaneous Commercial ServicesCommercial Services Operates as an association of investment professionals | Commercial Services |
CFA Society of San Francisco
 CFA Society of San Francisco Miscellaneous Commercial ServicesCommercial Services Provides educational services | Commercial Services |
Franklin Templeton Cos. LLC
 Franklin Templeton Cos. LLC Investment ManagersFinance Provides asset management services | Finance |
venBio Partners LLC
 venBio Partners LLC Investment ManagersFinance venBio invests in companies located in the United States. The firm focuses on companies operating in the fields of life sciences sectors. It participates in early to late stage transactions. The firm acts as a lead investor. | Finance |
SFJ Pharmaceuticals, Inc.
SFJ Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops pharmaceuticals drugs | Health Technology |
Broadhaven Capital Partners (Private equity)
Broadhaven Capital Partners (Private equity) Investment ManagersFinance Broadhaven Capital Partners invests in companies located in the United States. The firm focuses on financial services and technology sectors. It participates in seed and early equity investments. | Finance |
Aurinia Pharmaceuticals, Inc.
 Aurinia Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics | Health Technology |
CRISPR Therapeutics AG
 CRISPR Therapeutics AG BiotechnologyHealth Technology Develops gene-based medicines | Health Technology |
Vaxcyte, Inc.
 Vaxcyte, Inc. BiotechnologyHealth Technology Develops vaccines for infectious diseases | Health Technology |
Orbus Therapeutics, Inc.
Orbus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delevops products that treat rare diseases | Health Technology |
Franklin Templeton Switzerland Ltd. | |
Kesios Therapeutics Ltd.
 Kesios Therapeutics Ltd. BiotechnologyHealth Technology Provides biotechnology services | Health Technology |
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Develops and manufactures immuno therapies | Health Technology |
Attenua, Inc.
 Attenua, Inc. Pharmaceuticals: MajorHealth Technology Provides biopharmaceutical services | Health Technology |
Abingworth Bioventures GP Ltd.
Abingworth Bioventures GP Ltd. Other TransportationTransportation Provides marine cargo handling facilities | Transportation |
Jasper Tx Corp.
Jasper Tx Corp. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company which engages in enabling cures through hematopoietic stem cell therapy | Health Technology |
Vera Therapeutics, Inc.
 Vera Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which focuses on development and treatments for immunological & inflammatory diseases | Health Technology |
Trishula Therapeutics, Inc.
 Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures cancer curing drugs and antibiotics | Health Technology |
Entos, Inc.
 Entos, Inc. Packaged SoftwareTechnology Services Develops AI driven platform for drug discovery | Technology Services |
Jasper Therapeutics, Inc.
 Jasper Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company which engages in enabling cures through hematopoietic stem cell therapy | Health Technology |
Launch Therapeutics, Inc.
 Launch Therapeutics, Inc. Financial ConglomeratesFinance Provides investment and therapies development services | Finance |
